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The Human Immunodeficiency Virus (HIV) and Acquired Immune-deficiency Syndrome (AIDS) 
epidemic is one of the most devastating health crises of the modern time, affecting mostly the 
African continent. Non-communicable diseases such as hypertension (HTN) are also becoming 
increasingly important health threats in Sub-Saharan Africa (SSA) linked to a rapid 
epidemiological transition. In this study, the incidence of HTN and risk factors associated with 
blood pressure (BP) changes in HIV+ and uninfected (HIV-) Rwandan women were determined. 
Method:  
Participants were recruited in 2005 as an observational cohort, and measurements taken every six 
months to assess the effectiveness and toxicity of HAART in HIV+ women in Kigali, Rwanda. 
Clinical examination was conducted and socio-demographic information, blood pressure readings, 
anthropometric and laboratory risk factors were collected in 710 HIV+ and 224 HIV- women aged 
22 – 78 years. Of these, 662 HIV+ and 202 HIV- women met the inclusion criteria for this study. 
HTN incidence rates were estimated from 2005 to 2011. Generalized estimating equations were 
used to determine risk factors associated with systolic and diastolic blood pressure (SBP/DBP) 
changes over time.  
Results: 
In this analysis of 864 women, 202 (23%) were HIV- and 662 (77%) were HIV+ HAART-naïve at 
recruitment. Of the HIV+ participants, 497 (75%) were initiated on treatment by the end of the 
study in February, 2011. HIV- participants were significantly older than the HIV+ participants 
(median age 43 (33.8-49.4) vs. 35 (30.6-39.5) years; p < 0.001) and had on average higher SBP 
(119 SD (15) versus 116 SD (10) mmHg, p = 0.012) and higher DBP (73.3 SD (10.4) versus 71.2 
SD (7.5) mmHg, p = 0.0013) measurements at recruitment.  
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The incidence rate (IR) of HTN from 2005 to 2010 in HIV + participants on antiretroviral treatment 
was 7 cases per 1000 per person-years at risk (95% CI 4.2 – 10.9); for HIV- women the IR was 23 
cases per 1000 person-years (95% CI 15.3 – 36) and for HIV + patients HAART naive the IR was 3 
cases per 1000 person-years (95% CI 0.47 – 23.72). 
Being underweight was associated with a 3.1 mmHg decrease in mean SBP compared to being 
normal weight (95% -5.48 – (-0.68); p = 0.012) for HIV + participants on HAART. For every unit 
increase in monthly income, SBP increased by 2.34 mmHg (95 % CI 0.077- 4.75; p = 0.058) for 
the HIV + HAART naïve and by age (p < 0.0001) and income (p < 0.0001) for the HIV-. Being 
underweight decreases DBP by 1.59 mmHg compared to being normal weight (95% CI -3.17 – (-
0.013); p = 0.048) for the HIV+ on HAART. Being employed was associated with 5.1 mmHg 
decrease in DBP (95% CI -9.06 – (-1.14); p = 0.012) compared to not being employed for the 
HIV+ HAART naïve and for every year increase in age the HIV-, DBP increased by 0.2 mmHg (95 
% CI 0.018 – 0.327; p = 0.028) and with every unit increase in depression score, DBP decreased by 
0.02 mmHg (95 % CI -0.35 – (-0.02); p = 0.025). 
Conclusion:  
Incidence rates of HTN were higher in HIV- compared with HIV+ participants, most likely due to 
the older age of the HIV- study participants. The findings also show that socio-economic factors 
such as income and employment status and lifestyle factors such as BMI and depression were also 
associated with blood pressure changes. Therefore, efforts should be made in raising the awareness 
of potential modifiable risks, such as lifestyle factors, for prevention of HTN and blood pressure 
control.  
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CHAPTER ONE 
BACKGROUND AND INTRODUCTION 
1.1. BACKGROUND 
The Human Immunodeficiency Virus (HIV) and Acquired Immune-deficiency Syndrome 
(AIDS) epidemic is one of the most devastating health crises of modern times, affecting 
families and communities in all nations of the world (1). Sub-Saharan Africa (SSA) is home 
to 13% of the global population, but carries a disproportionate burden of HIV prevalence 
worldwide, with about 68% of all persons living with HIV being Africans. In Africa, about 
60% of infected adults are women (1). Gradually, highly active antiretroviral therapy 
(HAART) medications have become available in most African countries due to price 
reductions and increased availability of generic drug formulations (2). Availability of 
HAART gives new hope for optimal health for HIV-infected persons who have access to 
HAART medications in developed and most developing countries (3, 4). As access and 
availability to HAART improves in most African countries including Rwanda, HIV infection 
will become a chronic illness. In some countries, life expectancy has started to increase 
significantly in HIV infected patients (5-8). Since the introduction of Zidovudine in 1987, 
antiretroviral medication has improved the wellbeing of HIV infected persons due to durable 
virologic suppression (9). For instance, the median survival for a person diagnosed with HIV 
infection was 10 years in 1990 (8), but is now close to the life expectancy in the general 
population (5). 
However, it is of concern that HAART use has recently been repeatedly reported to increase 
the occurrence of metabolic and cardiovascular complications during the course of treatment 
(10-13). The metabolic syndrome has been defined by the International Diabetes Federation 
(IDF) as a cluster of central obesity, raised triglycerides, reduced HDL cholesterol, raised 
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fasting plasma glucose and increased blood pressure (14). The National Cholesterol 
Education Program (Adult Treatment Panel III) defines metabolic syndrome as the presence 
of three out of five of the following characteristics: abdominal obesity, elevated triglycerides, 
raised HDL cholesterol, elevated blood pressure and raised fasting glucose (15). 
Some of the cardiovascular complications that are, repeatedly reported in patients with HIV 
on HAART are elevated blood pressure or  hypertension reported as an emerging new threat 
to the health and well being of people living with HIV (16). .  and have become the focus of 
scientific debate (17-19). However, this debate remains controversial. Some studies have 
shown HAART use for HIV treatment to be associated with an increase in prevalence of 
cardiovascular diseases (CVD) (20). Furthermore, studies suggest that HTN with HAART 
use may be related to specific antiretroviral agents such as NNRTIs and longer term use of 
HAART (21-23). 
Raised blood pressure means that the arterial blood pressure is continually higher than the 
recommended level, 120/80 mmHg. One may have high blood pressure if just one of the two 
numbers is higher than it should be, in that case it is called isolated SBP (i.e 140/80 mmHg) 
or isolated DBP (i.e 120/100 mmHg) (24). For most people, there is no single cause for their 
high BP. Causes of raised BP are not exactly known; however, it is known that some lifestyle 
and / or environmental factors can affect one’s risk of developing it. For example eating too 
much salt, physical inactivity, and being overweight, and drinking alcohol and now HAART 
use. HTN is an independent risk factor for myocardial infarction, stroke, heart failure and 
kidney disease (25).  
The aim of this research was to examine the development of HTN, a contributor to the burden 
of heart disease, stroke and kidney failure and premature death and disability, in the era when 
access to HIV treatment and rapid scale-up of HAART became evident in Rwanda (26) and 
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life expectancy has improved. This study does not assess the effect of specific HAART 
regimens on the outcomes of interest, but has assessed the effects of commencing HAART on 
incidence of HTN among the studied population; it concentrates on socio-economic and 
lifestyle non-pharmacological modifiable risk factors that may be changed in order to prevent 
HTN occurrence. Although there are still geographical barriers to effective access to some 
healthcare programs, Rwanda’s health care services have improved within the last 10 years. 
This has led to a decline in HIV prevalence in Rwanda, attributed to strong political will and 
a leadership committed to improving health care infrastructure.  
1.2. LITERATURE REVIEW 
Although enormous challenges persist in the control of infectious diseases, non-
communicable diseases are increasingly becoming important health threats in SSA, linked to 
a rapid epidemiological transition (27). Since the beginning of the HIV epidemic in 1981, 25 
million people have died of AIDS globally until 2009 (WHO 2009). Untreated HIV infection 
was also found to be associated with pericardial disease and cardiomyopathy, which 
worsened as the infection progressed (28). Prendergast reported that 10 to 20% of HIV 
positive patients were affected by significant cardiac diseases, which were the causes of death 
for 5% of the patients (29). 
Following implementation of HAART in 1996 in developed countries, mortality due to AIDS 
decreased substantially as a result of the effectiveness of the therapy in providing sustained 
suppression of viral replication and preservation of immune system function (9, 30). With 
HAART use, complications of HIV infection such as cardiomyopathy and pericarditis have 
been remarkably reduced (31). Since then, considerable progress has been achieved 
worldwide, and the increased availability of therapeutic agents has led to about 5.2 million 
(36%) of the 15 million people in need of treatment in low and middle income countries 
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receiving HAART compared to 30% in 2008 (UNAIDS 2011). Most countries in SSA are 
working towards universal access to HAART, and Rwanda is among the top ten low and 
middle income countries (Botswana, Cambodia, Chile, Croatia, Cuba, Guyana, Namibia, 
Nicaragua, Rwanda and Slovakia) in achieving universal access to antiretroviral treatment by 
December 2010 (UNAIDS 2011). The Rwandan national guidelines eligibility criteria for 
ART initiation have recently changed twice. The first change was in 2007/2008, where 
eligibility was expanded from CD4+ counts <200 cells/µL and/or WHO stage III or IV with 
200-350 cells/µL, to CD4+ counts <350 cells/µL irrespective of WHO stage. In late 2012, 
eligibility was expanded further to include all persons with CD4+<500 cells/µL. 
As demonstrated in the paragraphs above, the significant benefit of HAART in decreasing 
morbidity and mortality is indisputable. As life-expectancy increases, HIV infected 
individuals have become gradually exposed not only to the effects of aging itself, but also to 
the influence of other environmental risk factors, which are known to act in the general 
population.  
HIV infected individuals, like the rest of the population, are living long enough to experience 
chronic diseases such as HTN, also known as high or raised blood pressure, an increasingly 
important medical and public health issue worldwide. HTN is a well-known risk factor for 
cardiovascular diseases (CVDs) such as myocardial infarction, heart and kidney failure, and 
stroke. It has been identified as the primary cause of around half of all deaths from stroke and 
heart disease (32) and was ranked recently as the third-highest global cause of disability in 
terms of disability-adjusted life years (33) and the second leading cause of death in Africa 
(WHO 2013) Global Health estimates 2013 http://www.who.int/healthinfo/global burden 
disease/en/)  
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According to WHO, in 2011NCDs accounted for 30% of the 9.5 million deaths, and 25.8% of 
the 65.4 million disability adjusted life years (DALYs) recorded in Africa. it has been 
projected that by 2030 NCDs will exceed communicable diseases as the most common cause 
of death in Africa (32).   
Every year, 9.4 million people die from HTN related complications (WHO 2013). 
Worldwide, the prevalence of HTN is highest in the African region at 46% of adults being 
from 25 and above years of age (WHO 2013).  
 
The graph above shows HTN proportions across the globe according to WHO continents. The 
African continent shows the highest rates in both male and female population. 
http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/ 
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The map above also depicts the prevalence of HTN across the world and per country. Most 
SSA countries are in orange and red, showing HTN prevalence greater than 40%. 
In 2000, 639 million people with HTN were living in developing countries, and the predicted 
number of adults with HTN by 2025 was estimated to increase to 1.15 billion in developing 
countries (33). Apparently, the expected number for 2015 might already have been reached. 
In 2008, the estimated number of HTN cases in SSA was 75 million, and thus about four 
times higher as compared to 2005 (34). From African countries there is evidence that few 
patients, irrespective of their HIV status, seem to have adequate knowledge of hypertension 
(35).  
HTN, as it is explained by the pathophysiology of HTN an area of active research attempting 
to explain its causes, is a chronic disease characterized by elevation of arterial blood pressure 
(diastolic and/or  systolic). HTN can be classified as either essential or secondary. Essential 
HTN indicates that no specific underlying medical cause can be found to explain the patient’s 
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condition. Secondary HTN indicates that high blood pressure is a result of another underlying 
condition. In this study, secondary HTN will be dealt with. 
Hypertension is thought to be caused by both genetic and environmental factors, with varying 
combinations in different individuals. Proposed environmental factors include exposure to 
chronic stress, obesity, alcohol and salt intake and physical inactivity. It is likely that 
environmental and lifestyle factors operate interactively rather than independently to promote 
HTN (36). 
Also recent little information on genetic variations or genes that are over or under expressed 
as well as the intermediary phenotypes that they regulate to cause high BP (37) shows that a  
number of factors increase the BP including obesity, insulin resistance, high alcohol intake, 
high salt intake, aging and perhaps sedentary lifestyle, stress, low potassium intake and low 
calcium intake. Furthermore, many of these factors are additive such as obesity and alcohol 
intake (38).   
Effective combination antihypertensive therapies include combined agents from the 
following pharmacological classes: thiazide diuretics, beta blockers, Angiotensin- converting 
enzyme (ACE inhibitors), Angiotensin II receptor blockers (ARBs), Calcium channel 
blockers and renin inhibitors. Other medications sometimes used to treat HTN are Alpha 
blockers, these medications reduce nerve impulses to blood vessels, reducing the effects of 
natural chemicals that narrow blood vessels. Alpha- beta blockers, in addition to reducing 
nerve impulses to blood vessels, they slow the heartbeat to reduce the amount of blood that 
must be pumped through the vessels. Other medications are central acting agents and 
vasodilators. The latter, works directly on the muscles in the walls of arteries preventing them 
from tightening and narrowing. The former prevent the brain from signalling the nervous 
system to increase the heart rate and narrow the blood vessels.  
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Thiazide diuretics act on the kidneys to help the body eliminate sodium and water, thus 
reducing blood volume. Beta blockers reduce the workload of the heart and open blood 
vessels causing the heart to beat slower and with less force. ARBs relax blood vessels by 
blocking the action not the formation of a natural chemical that narrows blood vessels. 
Persons with chronic kidney disease may benefit from having an ARB as one of their 
hypertensive regimens. Calcium channel blockers help relax the muscles of blood vessels and 
some slow the heartbeat. Calcium channel blockers may work better for older people and 
blacks than ACE inhibitors do alone. Renin inhibitors slows down the production of renin, an 
enzyme produced by kidneys that starts a chain of chemical steps that increases blood 
pressure.  In a  study that assessed the prevalence, awareness, treatment and control rate of 
HTN in HIV infected patients from Italy, it was found that nearly 30% of HIV adult out 
patients had HTN, more than the 1/3 of this population were unaware of their condition and 
more than 2/3 were uncontrolled (39). In another systematic review of the studies done in the 
general population from urban areas of SSA, in most studies it was found that less than 40% 
of people with high BP had been previously detected, of people already diagnosed with HTN 
< 30% were on treatment and < 20% of them had BP within the normal range (40). 
 
Concerns have been raised regarding a possible increased risk of CVD (HTN included) as 
part of the metabolic complications related to the use of HAART in HIV infected individuals 
(19, 41). But even before the introduction of HAART, , in the early epidemic, the 
components of metabolic syndrome have been recognized in patients living with HIV 
infection; such as low high density lipoprotein (HDL) and low density lipoprotein (LDL) 
cholesterol and elevations in triglycerides, more often were seen in those with advanced 
disease but also were seen in asymptomatic patients (42).  
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However, previous studies examining the effect of HAART on BP have reported conflicting 
results.  A study in Kenya reported a lower prevalence of 7.4%–11.2%, compared with a 
12.3%–19.0% from Nigeria. This may be related to a lower prevalence of hypertension in 
Kenya (12.3%) compared with Nigeria (14.5% and 20%–25%) (43). A large cross-sectional 
study has shown that non- nucleoside reverse transcriptase inhibitor (NNRTI) or protease 
inhibitors (PI) use were associated with HTN, but the association did not persist after 
adjusting for baseline characteristics such as age (44). Other studies suggested a lower risk of 
HTN among HIV infected patients receiving PIs compared with HIV uninfected individuals 
(45, 46). In studies that compared the prevalence of HTN among HIV positive patients 
receiving HAART to matched controls HIV positive not on HAART have shown increased 
prevalence of HTN and metabolic syndromes in  patients on HAART (47-49).  
The increase in life expectancy and alteration of lipid metabolism due to receipt of HAART 
are suspected to increase the prevalence of HTN and diabetes. On the other hand, direct 
effects of HIV associated nephropathy and thrombotic micro-angiopathy seem to play a 
major role in the development of this process (50). Drugs used for the treatment of the HIV 
infection that are associated with nephrotoxicity include aminoglycosides, amphotericin, 
foscarnet, trimetoprim-sulfamethoxazole, tenofovir, indinavir and acyclovir. Data on HTN in 
HIV infected patients on HAART in SSA are scarce, and few studies have assessed the 
occurrence of CVDs or HTN in these populations (51, 52). Metabolic complications and 
abnormal fat distribution have been frequently observed after a few years of HAART, and as 
the array of anti-retroviral drugs became broader, long term metabolic alterations are 
becoming far more common worldwide (11).   
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Given the extensive HAART roll-out, and reports from other studies of an association 
between HAART use and increasing blood pressure levels in HIV-infected patients (53), the 
incidence of HTN in the RWISA cohort from 2005-2010 was investigated by the researcher 
in order to assist the improvement of long-term management of patients with HIV infection, 
to prevent unfavourable cardiovascular outcomes. Lazar et al (28), in a cross-sectional study 
of the Rwanda Women Inter-association study and assessment (RWISA) cohort, assessed 
differences in arterial wave reflection, a marker of atherosclerosis, and noted no association 
of HIV infection with arterial stiffness. However, RWISA participants had had little exposure 
to HAART at the time of assessment (28).  
Risk factors considered in this analysis are age, sex, marital status, education level and 
income or employment. Anthropometric factors that were looked at are SBP, DBP, BMI, CD4 
cell count for HIV positive groups, HDL, LDL, triglycerides and other factors such as 
depression, oral contraceptive pill (OCP) use.  
Rwanda, like other SSA countries, has severe financial constraints, among others the costs of 
treating CVD and related disabilities, and access to health care. Therefore early diagnosis and 
adequate treatment of HTN will improve patients’ outcomes and prevent serious 
complications such as stroke, myocardial infarction, renal failure and heart failure.  
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CHAPTER TWO 
RESEARCH OBJECTIVES AND METHODOLOGY 
2.1. STUDY OBJECTIVE 
The aim of this research was to determine the incidence of HTN in HIV-infected and HIV-
uninfected participants, and to assess risk factors associated with systolic and diastolic blood 
pressure changes over a 5 year period in a cohort of Rwandan women. 
Research questions are:  
(i) Was  the incidence of HTN higher in HIV-infected participants compared to the 
incidence among HIV-uninfected participants, 
(ii) Is the incidence of HTN higher in HAART-treated than HAART-naïve participants? 
(iii) Are the same risk factors of HTN across the three groups?  
2.2. SPECIFIC STUDY OBJECTIVES: 
 
 To describe demographic, anthropometric and laboratory risk factors for hypertension 
in the HIV+ and HIV- participants at baseline in 2005. 
 To illustrate the blood pressure trends in HIV-uninfected, HIV-infected HAART-
treated, and HAART-naïve participants.  
 To estimate the incidence rates and determine risk factors for HTN in HIV-infected 
and uninfected participants. 
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2.3. RESEARCH METHODOLOGY 
2.3.1. Study design 
This research is a secondary data analysis of data from the Rwanda Women’s Inter-
association Study and Assessment (RWISA), an observational cohort designed to assess the 
effectiveness and toxicity of antiretroviral therapy in HIV infected Rwandan women.  
2.3.2. Data collection 
 
The research was conducted in Kigali, Rwanda between May 2005 and February 2011. Amid 
May 2005 and November 2005, 710 HIV infected and 226 HIV uninfected women, older 
than 15 years of age with no prior history of receiving HAART, and who gave informed 
consent, were enrolled in the RWISA cohort (54). The baseline study visit consisted of an 
interview, physical and gynaecological exam and collection of blood, urine and 
gynaecological specimens. The interviews were conducted in Kinyarwanda by trained 
interviewers with a background in nursing or counselling or both. Follow-up visits were 
scheduled every six months (55). At study enrolment, demographic characteristics were 
collected. A physical examination was conducted by trained staff following HIV guideline 
protocol of that time. Foe follow-up visits, anthropometric measurements such as CD4 count, 
weight and blood pressure were recorded at every visit attended. More details can be found in 
papers by JC Dusingize at al., and JM Lazar et al.  (54, 56). 
 
Data were entered directly into an ACCESS database through a user-friendly interface.  
Relevant data were extracted from the RWISA dataset to enable the researcher to answer the 
research question mentioned above. This secondary analysis included all study participants 
except those who at baseline had HTN (the outcome of interest) or were pregnant, and thus 
comprised 864 of the 936 participants who were enrolled.  
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2.3.2. Study procedures 
2.3.3. Definitions of variables 
Exposure 
HAART: eligible participants were initiated on different HAART regimens according to 
national guidelines during the follow-up study period. 
Outcome variable 
Hypertension was defined as systolic BP≥140 or diastolic BP≥90 mmHg and/or use of anti-
hypertensive medication. In particular, isolated SBP was defined as having SBP≥140 mmHg 
and DBP<90 mmHg. Isolated DBP was defined as having SBP<140 mmHg and DBP≥90 
mmHg as defined by WHO. Two blood pressure readings were collected at each visit, in a 
sitting position, and the average of the two readings was computed and used for this analysis. 
An individual was considered hypertensive if she had at least 2 raised BP during the study 
period. This may have occurred at two consecutive visits or at different visits i.e first and 
third visit, or patients seen outside the 6 months scheduled visits initially.  
Explanatory variables 
Demographic variables were: age, marital status (single, married and widowed), level of 
education (no education, primary and secondary or more), employment and income. 
Anthropometric and laboratory variables included: blood pressure measures, weight and 
height translated into body mass index (BMI), CD4+ cell counts, plasma total cholesterol 
levels, high density lipoprotein cholesterol (HDL) levels, low density lipoprotein cholesterol 
(LDL) levels, and plasma triglyceride levels. Total cholesterol, triglycerides and high-density 
lipoprotein levels were measured in fasting blood samples. Low-density lipoprotein (LDL) 
was calculated from Friedewald equation if triglycerides < 400 and measured directly if 
triglycerides ≥ 400 mg/dl (57). Other cardiovascular risk factors included depression, 
measured as a continuous variable as per the Center of Epidemiologic Studies Depression 
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Scale (CES-D) (55), later assessed as an ordinal scale ranging from 0 to 2; 0 being normal, 1 
mild to moderate depression and 2 major depression; and use of the oral contraceptive pill 
(OCP). 
2.4. STATISTICAL ANALYSIS 
After extraction from the original dataset, data were transferred into STATA 12 (StataCorp, 
College station, Texas, USA) for data cleaning and further statistical analysis. Baseline 
demographic and clinical characteristics were described using mean ± standard deviation 
(SD) or median (inter-quartile range) for continuous variables, and frequencies with 
percentages for categorical variables. Associations between variables were assessed using the 
chi-squared test or Fisher’s exact test for categorical variables and Student’s t-test for 
normally distributed variables or the Wilcoxon ranksum test when the normality assumption 
did not hold for continuous variables. For illustration of blood pressure changes over time in 
all the three groups, mean systolic and diastolic BP were computed for different visits: at 
baseline, at visit 3 (first year of follow-up), at visit 5 (second year of follow-up) and at visit 8 
(fifth year of follow-up). All anthropometric measurements (BP included) recorded from 
baseline or at enrolment and at each follow-up study visit were included in this analysis.  
The line graphs were used to depict the mean systolic and mean diastolic BP trends at 
baseline, at one year, two years and five years of follow-up for the 3 groups respectively: 
HIV negative, HIV positive not initiated on treatment (HAART-naïve), and HIV positive on 
HAART, according to age categories. Analysis of variance (ANOVA) was performed to 
assess the information given by the graphical displays.  
Survival analysis was used to compute the incidence rate (IR) of HTN, for the HIV positive 
on HAART group of participants was calculated by dividing the total number of cases of 
HTN by the total time spent in the study from the time of HAART initiation till when 
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participants developed HTN and were censored. The IRs of HTN for HIV negative and 
positive HAART-naïve participants were computed by dividing the total number of cases of 
HTN for each of the two groups by the total number of person-years of follow-up spent from 
the time of enrolment in the study till the development of HTN, the outcome of interest.   
Univariable and multivariable analyses were conducted to investigate the risk factors 
associated with systolic and diastolic BP changes in HIV infected women on HAART from 
the cohort using generalized estimating equations (GEE) models, with identity link as the link 
function, a Gaussian family and an unstructured working correlation structure. Further details 
on the GEE procedures are described in appendix A. All risk factors with p < 0.20 in the 
univariable models were included in the multivariable analyses. In the models, only subjects 
with non-missing values in all variables were considered and statistically significant 
associations were defined as those with p < 0.05. Further, sequential analysis was performed 
to look for other risk factors that might not have been found significant in earlier analysis, yet 
were shown to be significantly associated with HTN development in the literature review 
using the Bonferroni post hoc test. Parameters of all individuals that were present at each visit 
were included in the analysis. 
2.5. ETHICAL CONSIDERATIONS 
Informed consent was obtained from all participants included in the primary study, according 
to the protocols approved by the Rwandan National Ethics Committee and the Institutional 
Review Board of Montefiero Medical Center, Bronx, NY, USA. All participants in the 
present study were identified by a unique identifier in the dataset, and all personal identifiers 
were removed from the dataset before the secondary data analysis took place to maintain 
confidentiality.  
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Ethical clearance for the secondary data analysis was issued by the Human Research Ethics 
Committee, University of Witwatersrand (Appendix B) and the Rwandan National Ethics 
Committee, with permission to use the RWISA dataset by the Supervisor of the Project. 
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CHAPTER THREE 
RESULTS OF THE RESEARCH 
3.1. INTRODUCTION  
This chapter presents the research findings. Section 3.1. reports on the analysis of baseline 
characteristics of all study participants stratified by HIV status, bearing in mind that all 
participants were either HIV negative or HIV positive and no one was on HAART yet. 
Section 3.2. presents and analyses the BP trends within different HIV groups according to 
their age categories and compares the age categories of different HIV groups. IRs are 
stratified by age and BMI categories according to HIV status in section 3.3., and predictors of 
mean SBP and mean DBP changes during the course of the study are presented according to 
HIV status and treatment group in section 3.4. 
3.1.1. BASELINE CHARACTERISTICS OF THE STUDY PARTICIPANTS 
Demographic characteristics 
Demographic characteristics of the study participants are shown in Table 1. There were 936 
women aged 20 years and above who participated in the RWISA study. Of these, 52 were 
hypertensive and 20 women were pregnant at baseline. These 72 women were, therefore, 
excluded from the secondary analysis. The cohort for the current analysis consisted of 864 
women. Of these, 202 (23%) were HIV negative, and 662 (77%) were HIV positive 
participants who were HAART-naïve at study enrolment. Of the 662 HIV positive study 
participants, 497 (75%) were initiated on HAART by the end of the study. HIV negative 
participants were significantly older (median 43 years) than HIV positive participants 
(median 35 years) (p < 0.001).  
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Age (years), median(IQR)  42.7 (33.8-49.4)  34.6 (30.6-39.5) <0.001 
































Employment status, n (%)   









Monthly income, n (%)  
< 10 000 RWFs (18USD$) 
10 000 – 35 000 (18 - 60) 













Anthropometric and lab variables: 














), median(IQR) 20.7 (18.5-23.3) 21.1 (19.1-23.4) <0.001 
Serum cholesterol (mg/dL),  









































Depression score, mean±SD) 33±11.9 37±9.5 <0.001 
Levels of CD4+, n (%) 
<200 CD4+ cells/μL 
200-350  CD4+ cells/μL 






















For all categorical variables, n (%) are reported. For continous variviables, data are expressed as mean±SD 
and medians with IQR. SBP: systolic blood pressure, DBP: diastolic blood pressure, Body Mass Index 
(BMI) was calculated by dividing the weight in Kilograms by the square of the height in meters (kg/m
2
). 
HDL: high density lipoprotein, LDL: low density lipoprotein cholesterol. To convert the values for 
cholesterol to mmol/L, multiply by 0.02586. To convert the values for triglycerides to mmol/L, multiply by 
0.01129. NA: not applicable. NB: p-values were computed without missing values.  
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More than half of the participants in both groups were widowed 55% vs 58% (p < 0.003). 
Although the percentage of widows is quite similar in both HIV status groups, there is a 
significant association between HIV status and marital status (p = 0.003). Specifically, the 
percentage of married women is higher in the HIV- group: 20% HIV- women are married 
while only 12% HIV+ women are married. This pattern is reversed in the group of single 
women where only 17% HIV- women are single and 26% HIV+ women are single. The 
HIV+ group had a lower percentage of individuals with no formal education level (23% vs. 
29%). There was no significant difference in employment status between HIV- and HIV+ 
participants (p = 0.729). Of those who worked, 43% of HIV- participants earned less than 18 
US$ per month, compared to 36% of the HIV+ participants.  
Baseline anthropometric and laboratory variables 
The results for baseline anthropometric and laboratory variables are presented in Table 1. 
There were statistically significant differences between HIV negative and HIV positive 
participants in mean SBP (119±15 vs. 116±10 mmHg, p = 0.012) and in mean DBP 
(73.3±10.4 vs. 71.2±7.5 mmHg, p = 0.0013) respectively. HIV negative and HIV positive 
participants differed in median BMI (20.7vs. 21.1 kg/m
2
, p < 0.001), in mean total cholesterol 
level (142±37 vs. 130±34 mg/dl, p<0.001), in median HDL level (p < 0.001), in median 
triglyceride level (p = 0.006), and in mean depression score (p < 0.001).  
Figure 1 shows the numbers of participants who attended each visit. The numbers decreased 
with time from 864 (202 HIV negative and 662 HIV positive) participants at the first visit to 
583 (148 HIV negative and 435 HIV positive) participants at the eighth visit, with the sixth 
visit being the least attended because of budget issues at that time. Therefore, the sixth visit 
was excluded from the analysis. On average, participants were seen four times. Taken 
together, all individuals contributed 5339 readings of systolic and diastolic BP. The median 
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time of follow-up for the cohort was 5.10 years (IQR 3.12-5.32) for the whole cohort, and the 
median time on HAART was 3.37 years (IQR 2.07-4.90). 
 
Figure 1: Number of participants per each study visit by HIV status over the study period.  
3.2. BLOOD PRESSURE TRENDS OF THE THREE GROUPS OVER TIME 
To conduct an analysis of SBP and DBP trends over time, the time points were chosen at one 
year intervals. However, because of lack of funds after the second year, there was a gap for 
year three and four. Hence, visit seven and eight were done in year five. Only four visits were 
considered for this analysis: visit one (baseline), visit three (year one), visit five (year two), 
and visit eight (year five).   
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Figure 2: SBP trends for the HIV negative, HIV positive on HAART and HIV positive 









1 3 5 8
1 3 5 8
HIV neg HIV pos on HART













Figure 3: DBP trends for the HIV negative, HIV positive on HAART and HIV positive 
HAART naïve groups and per  age categories throughout the study period.  
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Figure 2 and 3 show systolic and diastolic BP trends per age categories for HIV-, HIV+ on 
HAART, and HIV+ HAART- naïve study groups. Overall, both SBP and DBP increased with 
age in all three studied groups throughout the four visits. The 50 years and above age 
category had higher mean SBP and DBP in all the three studied groups. SBP and DBP 
followed similar trends over time visits. 
In general, the figures show that similar SBP and DBP trends are observed over the visits for 
the three HIV groups. The mean BP decreased from the baseline visit to the first year and 
from the second year to the fifth year and increased from the first year to the second year of 
follow-up. Participants over 50 years of age had higher mean SBP and DBP measurements 
compared to the other age categories.  
The patterns of the graphs were similar in the three HIV study groups, mainly for mean SBP 
and to some extent for mean DBP. A three-way analysis of variance (ANOVA) was 
performed to test the information given by the graphical displays, where the response variable 
was either the mean SBP or the mean DBP and the explanatory variables were age groups, 
HIV groups, and visits. For mean SBP, the ANOVA showed no significant differences 
between HIV study groups (p = 0.085), whereas significant differences between age 
categories (p < 0.0001) and between visits (p < 0.0001) were noted. The assessment of age 
categories with significantly different mean SBPs was conducted using the Bonferroni 
multiple comparison test. The test showed that participants aged 50 years and above had a 
mean SBP higher than the other three age categories (p < 0.0001). The result confirmed what 
was obtained from the exploration of the graphs in Figure 2. In addition, participants aged 40-
50 years had higher mean SBP than those aged 30-40 years (p = 0.023). Similarly, the 
Bonferroni test showed that the mean SBP at visit eight was significantly lower than the 
mean SBP for the other three visits (p < 0.0001), and the mean SBP at visit three was 
significantly lower than the mean SBP at visit one and five (p < 0.0001).  
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For mean DBP, a significant difference between age categories, visits, and HIV study groups 
was also observed. The Bonferroni test showed that participants aged 50 years and above had 
a higher mean DBP than participants aged less than 30 years (p = 0.004), 30- 40 years (p < 
0.0001) and 40- 50 years (p = 0.002). The mean DBP at visit eight was significantly lower 
than the mean DBP at the other three visits (p < 0.0001). In addition, the mean DBP was 
significantly lower at visit three than at visits one and five (p < 0.0001). The Bonferroni test 
also showed that the mean DBP was higher for HIV- patients than the mean DBP for HIV+ 
patients on HAART and HIV+ HAART-naïve patients (p < 0.0001). 
Figures 4 and 5 compare the same age categories for different HIV groups (HIV-, HIV+ on 
HAART, and HIV+ HAART-naïve). For both SBP and DBP a decrease from the fifth visit 
(second year) to the eighth visit (fifth year) was noted. Thus, ANOVA was performed to 
assess whether the information displayed by the graphs was due to visits or HIV status 
groups. The results showed no significant differences between HIV study groups (p = 0.275),  
but showed significant differences between visits (p < 0.0001). To assess which visits were 
significantly different, the Bonferroni test showed that visit eight was significantly different 
from other visits with respective p-values of < 0.0001, 0.005 and < 0.0001. For DBP, similar 
analyses were performed, showing a significant difference between visits (p = 0.0001) and 
between the studied groups (p = 0.013). A three-way ANOVA showed significant differences 
between visits one and eight (p = 0.001) and between visits five and eight (p < 0.0001). 
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Figure 5: DBP trends per age categories and per study groups throughout the study period. 
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3.3. INCIDENCE RATES OF HYPERTENSION IN THE THREE STUDIED GROUPS 
FROM THE COHORT 
There were in total 39 HTN cases. Of these, 17 incident cases were observed among the 592 
HIV+ participants initiated on HAART, one from the 113 HIV+ HAART-naïve participants 
and 21 from the 225 HIV- participants. The incidence rates (IRs) for HTN were found to be 
seven cases (95% CI 4.22; 10.91), three cases (95% CI 0.41; 23.72), and 23 cases (95% CI 
15.34; 36.08) per 1000 person-years at risk in HIV+ on HAART, HIV+ HAART-naïve and 
HIV- participants respectively.    
HIV- participants were on average considerably older at study recruitment (Table 1). Hence, 
it was assessed whether incidence rates between the HIV- and HIV+ on HAART groups 
differed because of the different age distribution for HIV positive and negative participants 
(Table 2). BMI effects on incidence rates of the two groups were also assessed. HIV+ 
HAART-naïve patients were not considered as they had a very low HTN incidence rate. 
Table 2: Incidence of hypertension by age and BMI categories 
Incidence rates HIV neg 
n=202 
HIV pos on HAART 
n=475 







5 (0.7; 34.5) 
23 (10.9; 47.8) 
41 (23.8; 70.6) 
 
0 
5 (2.5; 10.9) 
8 (3.6; 17.7)  









18 (4.4; 70.3) 
20 (9.7; 42.9) 
24 (6.1; 97.7) 
61 (15.3; 244.0) 
 
 
4.7  (0.7; 33.2) 
5.6 (2.5; 12.5) 
10.9 (3.5; 33.7) 
17.9 (2.5; 126.8) 
IRs are presented as number of cases per 1000 person-years with their 95% CIs. BMI or Body 
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The results in Table 2 show that IRs of HTN increased with age for both HIV- participants 
and HIV+ participants on HAART. However, IRs of HTN for the 40-50 and ≥ 50 year age 
categories were considerably higher in the HIV- group compared to the HIV+ on HAART 
group. Assessment of the influence of BMI on HTN indicated increased risk of HTN with 
overweight and obesity (Table 2).  
3.4. SYSTOLIC BP CHANGES WITHIN THE THREE HIV STUDY GROUPS 
Univariable and multivariable analyses of the association between SBP changes and 
demographic, anthropometric and laboratory HTN risk factors are summarized in Tables 3 to 
5. All the risk factors with associations at p < 0.2 in the univariable analysis were added in 
the multivariable analysis. 
3.4.1. SBP CHANGES FOR HIV+ PARTICIPANTS ON HAART 
Table 3 shows the risk factors for SBP changes for the HIV+ participants on HAART over 
the study period. In the unadjusted analysis of demographic characteristics, for every one 
year increase in age, SBP increased by 0.1 mmHg (95% CI 0.04; 0.17) (p = 0.001). Having a 
primary level of education was associated with an increase of 2.1 mmHg (95% CI 0.05; 4.15) 
(p = 0.04) in SBP compared to no education level, while having a secondary level of 
education was associated with an increase of 3.5 mmHg (95% CI 0.18; 6.86) (p = 0.04) in 
SBP compared to no education level. For every unit increase in monthly income, SBP 
increased by 0.7 mmHg (95% CI 0.28; 1.09) (p = 0.001). In the unadjusted analysis of 
clinical and laboratory variables, being underweight was associated with a decrease of 2.2 
mmHg (95% CI -3.29; -1.02) (p < 0.001) in SBP compared to having a normal weight, and 
being overweight was associated with an increase of 1.2 mmHg (95 % CI 0.09; 2.23) (p < 
0.001) in SBP, compared to having a normal weight. Being obese was found to be associated 
with an increase of 4.4 mmHg (95% CI 2.1; 6.6) (p < 0.001) in SBP compared to having a 
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normal weight. For every unit increase in depression score, SBP increased by 0.05 mmHg 
(95% CI 0.03; 0.06) (p < 0.001).
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Table 3: Risk factors for  SBP changes in HIV+ on HAART participants over the study period. 
RISK FACTORS  UNIVARIABLE ANALYSIS MULTIVARIABLE ANALYSIS 
n = 475 
 Coef 95% CI P Coef 95% CI P 
Demographic characteristics: 

















   

















































Monthly income 0.7 0.28; 1.09 0.001 0.21 -0.80; 1.24 0.677 
Anthropometric and laboratory variables: 
CD4+ 0.002 -0.001; -0.004 0.133 0.004 -0.002; 0.011 0.155 
BMI categories: 
Normal weight 
(BMI≥18.5 & BMI<25) 
Underweight 
(BMI<18.5) 






























































































Plasma glucose (mg/dL) 0.016 -0.002; 0.033 0.086 0.016 -0.003; 0.035 0.1 
















Depression score 0.05 0.03; 0.06 <0.001 0.005 -0.107; 0.098 0.931 
Coef = coefficient, P = p-value, Ref = reference group. HDL: High density lipoprotein, LDL: Low 
density lipoprotein cholesterol. To convert the values for cholesterol to mmol/L, multiply by 0.02586. 
To convert the values for triglycerides to mmol/L, multiply by 0.01129. OCP: oral contraceptive pill. 
 
The multivariable analysis showed that being underweight was associated with a 3.1 mmHg 
decrease in mean SBP compared to being of normal weight (95% CI -5.48; -0.68) (p =0.012). 
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All the other predictor variables were found not statistically significant for SBP after 
adjustment, as all associations had p-values > 0.05. However, by eliminating non-significant 
variables sequentially, starting with variables with the highest p-values, it was found that as 
age increased, mean SBP increased by 0.19 mmHg (95% CI 0.13; 0.25) (p < 0.0001) per 
year. With normal weight as the referent, being underweight was associated with a decrease 
of 2.53 mmHg (95% CI -3.66; -1.41) (p < 0.001), while being overweight was associated 
with an increase of 1.11 mmHg (95% CI 0.06; 2.17) (p < 0.038), and being obese was 
associated with an increase of 4.05 mmHg (95% CI 1.82; 6.63) (p < 0.001) in SBP. 
3.4.2. SBP CHANGES FOR HIV HAART-NAÏVE PARTICIPANTS 
Table 4 shows the univariable and multivariable analysis for demographic, anthropometric 
and laboratory risk factors associated with SBP changes for HIV+ participants not on 
HAART. In the unadjusted analysis for demographic characteristics, being employed was 
associated with 3.8 mmHg increase in SBP (95% CI 1.7; 5.9) (p < 0.001) compared to not 
being employed. In the unadjusted analysis for clinical and laboratory variables, being obese 
increased SBP by 3.75 mmHg (95% CI 0.03; 7.48) (p = 0.048) compared to having a normal 
weight. For every unit increase in serum HDL, SBP increased by 0.2 mmHg (95% CI 0.04; 
0.29) (p = 0.008). For every unit increase in depression score, SBP increased by 0.08 mmHg 
(95% CI 0.06; 0.12) (p < 0.001).   
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Table 4: Risk factors for SBP changes for HIV+ HAART-naïve participants over the study 
period. 
RISK FACTORS  UNIVARIABLE ANALYSIS MULTIVARIABLE  ANALYSIS 
n=187 
 Coef 95% CI  P Coef 95% CI P 
Demographic characteristics: 


































   
Employment status 3.79  1.68; 5.90 <0.001 0.76 -4.83; 6.36 0.789 
Monthly income  0.75 -0.23; 1.72 0.133 2.34 0.08; 4.75 0.058 
Anthropometric and laboratory variables: 
































































Plasma triglycerides 0.0003 -0.013; 0.013 0.971    
Glucose 0.006 -0.02; 0.03 0.639    
OCP use 0.78 -5.74; 7.31 0.814    
Depression score 0.08 0.06; 0.12 <0.001 -0.12 -0.38; 0.14 0.374 
Coef=coefficient, P=p-value, Ref=reference group. BMI or Body Mass Index was calculated by dividing 
the weight in Kilograms by the square of the height in meters (kg/m
2
). To convert the values for 
cholesterol to mmol/L, multiply by 0.02586. To convert the values for triglycerides to mmol/L, multiply 
by 0.01129. CD4+ cell count, HDL: high density lipoprotein, LDL: low density lipoprotein cholesterol, 
OCP: oral contraceptive pill. 
 
The multivariable analysis showed that of seven risk factors with associations at p < 0.2 in 
the bivariate analysis, only the monthly income was found to be a marginally significant 
predictor of SBP. For every unit increase in monthly income, the SBP for HIV+ participants 
not on HAART increased by 2.34 mmHg (95 % CI 0.08; 4.75) (p = 0.058).   
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By eliminating non-significant variables sequentially, starting with variables with the highest 
p-values, it was found that HDL increased SBP by 0.158 mmHg (95% CI 0.032; 0.283) (p = 
0.014). 
3.4.3. SBP CHANGES FOR HIV NEGATIVE PARTICIPANTS 
Table 5 shows the univariable and multivariable analyses of demographic, anthropometric 
and laboratory risk factors associated with SBP changes for HIV negative participants.  The 
unadjusted analysis for systolic BP and demographic characteristics showed that for every 
year increase in age, SBP increased by 0.2 mmHg (95% CI 0.11; 0.28) (p < 0.001). Having a 
monthly income was associated with 1.1 mmHg increase in SBP (95% CI 0.442; 1.773) (p = 
0.001).  
In the unadjusted analysis of clinical and laboratory variables, being obese increased SBP by 
5.6 mmHg (95% CI 1.67; 9.47) (p = 0.005) compared to having a normal weight. The 
multivariable analysis showed that no predictor variable was statistically significant in 
explaining SBP changes of HIV- participants since all p-values were > 0.05. However, by 
sequentially eliminating non-significant variables, starting with those having the highest p–
values, it was found that as age increased, mean SBP increased by 0.29 mmHg (95% CI 0.19; 
0.40) (p < 0.0001), and for every unit increase in income, SBP increased by 1.40mmHg (95% 
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Table 5: Risk factors for SBP changes for HIV- participants over the study period. 
 
 
RISK FACTORS UNIVARIABLE ANALYSIS MULTIVARIABLE ANALYSIS 
n = 202 
 Coef 95% CI P Coef 95% CI P 
Demographic characteristics: 

















































Monthly income 1.1 0.442; 1.773 0.001 0.000 -0.077; 0.077 0.998 
Anthropometric and laboratory variables: 
CD4+ 0.002 -0.0008; 0.005 0.163    
BMI categories: 


















































   
Plasma triglycerides  0.006 -0.027; 0.039 0.723    
Plasma glucose  -0.02 -0.05; 0.005 0.119 -0.02  -0.049; 0.01 0.197 














Depression score 0.004 -0.029; 0.038 0.801    
Coef=coefficient, P=p-value, Ref=reference group. To convert the values for cholesterol to mmol/L, 
multiply by 0.02586. To convert the values for triglycerides to mmol/L, multiply by 0.01129. CD4+ cell 
count, HDL: High density lipoprotein, LDL: Low density lipoprotein cholesterol, OCP: oral 
contraceptive pill. 
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3.5. DIASTOLIC BP CHANGES WITHIN THE THREE HIV STUDY GROUPS 
Univariable and multivariable analyses for factors in DBP changes for HIV + on HAART, 
HIV+ HAART-naïve and HIV- participants are presented in Tables 6 to 8. All risk factors 
associated with DBP at p < 0.2 in the univariable analysis were added in the multivariable 
analysis. 
3.5.1. DBP CHANGES FOR HIV+ PARTICIPANTS ON HAART 
Table 6 shows the univariable and multivariable analysis of demographic, anthropometric and 
laboratory risk factors associated with DBP changes for HIV+ patients on HAART.   
In the bivariate analysis for diastolic BP and demographic characteristics, for every year 
increase in age, DBP increased by 0.06 mmHg (95% CI 0.02; 0.09) (p = 0.007). Having a 
secondary level of education was associated with an increase of 2.3 mmHg in DBP (95% CI 
0.07; 4.7) (p = 0.06) compared to having no education. For every unit increase in monthly 
income, DBP increased by 0.5 mmHg (95% CI 0.2; 0.8) (p = 0.001). The unadjusted analysis 
of clinical and laboratory variables showed that being underweight was associated with a 
decrease of 1.49 mmHg (95% CI -2.23; - 0.75) (p < 0.001) in DBP, while being obese was 
associated with an increase of 2.92 mmHg (95% CI 1.44; 4.38) (p < 0.001) in DBP, both 
comparisons with reference to having a normal weight. For every unit increase in depression 
score, DBP increased by 0.04 mmHg (95% CI 0.02; 0.05) (p = 0.001).  
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Table 6: Risk factors for DBP changes for HIV+ on HAART participants over the study 
period. 
RISK FACTORS UNIVARIABLE ANALYSIS MULTIVARIABLE ANALYSIS 
n = 475 
 Coef 95% CI P Coef 95% CI P 
Demographic characteristics: 

















   








































   
Monthly income  0.48 0.20; 0.75 0.001 0.29 -0.74; 1.33 0.575 
Clinical and other related variables: 































































0.0004 -0.002; 0.003 0.72    
Plasma glucose  -0.005  -0.018; 0.008 0.49    





















Depression score 0.04 0.02; 0.05 <0.001 0.011  -0.061; 0.84 0.762 
Coef=Coefficient, P=p-value, Ref=reference group. To convert the values for cholesterol to 
mmol/L, multiply by 0.02586. To convert the values for triglycerides to mmol/L, multiply by 0.01129. 
HDL: high density lipoprotein, LDL: Low density lipoprotein cholesterol, OCP: oral contraceptive pill. 
 
The multivariable analysis found that no predictor variable was statistically significant in 
explaining DBP changes in HIV+ on HAART participants as all the p-values were > 0.05. 
However, by eliminating non-significant variables sequentially, starting with variables with 
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the highest p–values, it was found that being underweight decreased DBP by 1.59 mmHg 
(95% CI -3.17; -0.013) (p = 0.048). 
3.5.2. DBP CHANGES FOR HIV HAART-NAÏVE PARTICIPANTS 
Table 7 shows the univariable and multivariable analysis of demographic, anthropometric and 
laboratory risk factors associated with DBP changes for HIV+ HAART-naïve participants.   
In the unadjusted analysis of demographic characteristics, being employed was associated 
with a 1.9 mmHg increase in DBP (95% CI 0.5; 3.3) (p = 0.009), compared to not being 
employed. In the unadjusted analysis of clinical and laboratory variables, no clinical or 
laboratory predictor variable was found to be statistically significant to explain DBP change 
since all the p -values were > 0.05. 
The multivariable analysis showed that being employed was the only statistically significant 
explanatory variable for DBP change in HIV+ HAART-naïve patients. Being employed was 
associated with 5.1 mmHg decrease in DBP (95% CI -9.06; -1.14) (p = 0.012) compared to 
not being employed. Subsequent sequential elimination did not improve the predictive value 
of any other variable. 
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Table 7 Risk factors for DBP changes for HIV+ HAART-naïve participants over the study 
period. 
RISK FACTORS  UNIVARIABLE ANALYSIS  MULTIVARIABLE ANALYSIS 
n = 187 
 Coef 95% CI P Coef 95% CI P 
Demographic characteristics:  

















   






































Monthly income  -0.2 -0.73; 0.43 0.608    
Anthropometric and laboratory variables 





















   

























Plasma triglycerides 0.007 -0.002; 0.017 0.141 0.015 -0.031; 0.06 0.532 
Glucose 0.0007 -0.017; 0.018 0.941    
OCP use 1.2 -3.564; 5.952 0.623    
Depression score 0.01 -0.026; 0.045 0.601    
Coef=coefficient, P=p-value, Ref=reference group. To convert the values for cholesterol to mmol/L, 
multiply by 0.02586. To convert the values for triglycerides to mmol/L, multiply by 0.01129. CD4+ cell 
count, HDL: high density lipoprotein, LDL: Low density lipoprptein, OCP: Oral contraceptive pill. 
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3.5.3. DBP CHANGES FOR HIV NEGATIVE PARTICIPANTS 
Table 8 shows the univariable and multivariable analyses of demographic, anthropometric 
and laboratory parameters risk factors associated with DBP changes for HIV negative 
participants.   
In the unadjusted analysis for DBP and demographic characteristics, for every year increase 
in age, DBP increased by 0.1 mmHg (95% CI 0.06; 0.16) (p < 0.001). Being employed was 
associated with a 2 mmHg decrease in DBP (95% CI -3.12; -0.54) (p = 0.005) compared to 
not being employed. Having a monthly income was associated with 1 mmHg increase in DBP 
(95 % CI 0.60; 1.5) (p < 0.001). In the unadjusted analysis of anthropometric and laboratory 
variables, being overweight was non-significantly associated with a 2.1 mmHg increase in 
mean DBP compared to having a normal weight (95% CI -0.175; 4.38) (p = 0.07). Being 
obese was associated with 5.6 mmHg increase in mean DBP compared to having a normal 
weight (95% CI 1.67; 9.47) (p = 0.005). The use of OCP decreased DBP by 4.9 mmHg (95% 
CI -9.2; -0.5) (p = 0.029) compared to no use. 
In the multivariable analysis DBP was explained by age and depression score. With every 
year increase in age, DBP increased by 0.2 mmHg (95% CI 0.02; 0.33) (p = 0.028), and with 
every unit increase in depression score, DBP decreased by 0.02 mmHg (95% CI -0.35; -0.02) 
(p = 0.025). However, by eliminating non-significant variables sequentially starting with 
variables with the highest p-values, it was found that, in addition to age and depression score, 
for every unit increase in income, DBP increased by 1.21 mmHg (95% CI 0.77;1.66) (p < 
0.0001).   
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Table 8:Risk factors for DBP changes for HIV- participants over the study period. 
RISK FACTORS UNIVARIABLE ANALYSIS MULTIVARIABLE ANALYSIS 
n = 202 
 Coef 95% CI P Coef 95% CI P 
Demographic characteristics: 

















































Monthly income 1.05 0.607; 1.501 <0.001 1.2 -0.232; 2.692 0.099 
Anthropometric and laboratory variables: 
CD4 0.002 -0.005; 0.003 0.138 -0.002 -0.006; 0.003 0.504 
BMI categories: 


















































   






   















Depression score -0.02 -0.046; 0.005 0.116 -0.2 -0.35; -0.02 0.025 
Coef=coefficient, P=p-value, Ref=reference group. HDL: high density lipoprotein, LDL: low density 
lipoprotein cholesterol. To convert the values for cholesterol to mmol/L, multiply by 0.02586. To 
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CHAPTER FOUR: DISCUSSION 
4.1. INTRODUCTION 
To date, most studies assessing the relationship between HIV infection and treatment with 
blood pressure and HTN conducted in Sub-Saharan African countries have focused on the 
prevalence of HTN rather than on the incidence. The findings from this analysis have 
broadened our understanding of the incidence of HTN in both HIV infected and uninfected 
Rwandan women indicating that the incidence of HTN is higher in older HIV- participants. In 
addition, the study investigated the predictors of systolic and diastolic BP changes over a 
period of five years in the three HIV study groups: HIV negative participants, HIV positive 
participants HAART naive, and HIV positive participants on HAART. Age, BMI, 
employment status and monthly income were risk factors found to influence systolic and 
diastolic BP changes.  
4.2. SYSTOLIC AND DIASTOLIC BP TRENDS ACCORDING TO HIV GROUPS 
AND AGE GROUPS 
Systolic and diastolic BP trends were stratified according to HIV and age groups. Similar 
systolic and diastolic BP trends were observed throughout the study period, after one year, 
after two years and after five years in the three subject groups. Regarding the differences 
between the visits, it was noted that after five years systolic and diastolic BP were 
significantly different from the rest of the visits for both systolic and diastolic BP values. 
Systolic and diastolic BP measurements over the follow-up period decreased from baseline 
visit to visit three, from visit five to visit eight whereas both systolic and diastolic BP showed 
an increase from visit three to visit five, suggesting probable systematic measurement errors 
during the course of the study or some improvement in living conditions or it may be due to 
the fact that HIV infection was shown to be associated with a lower BMI and, thus, a lower 
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prevalence of raised BP compared with HIV-negative subjects. This also aligns with the fact 
well established that HIV is associated with weight loss and wasting (58). Another probable 
factor would be that the Rwandan population is slender in general, thus both systolic and 
diastolic BPs were in the normal range from baseline.  
4.3. INCIDENCE OF HYPERTENSION  
The incidence rates for HTN were observed to be higher in HIV- women (23 cases per 1000 
person-years) than in HIV+ patients on HAART (7 cases per 1000 person-years) and HIV+ 
patients not on HAART (3 cases per 1000 person-years). Similar results were found in a 
South African study that showed HIV negative women being more likely to be hypertensive 
than HIV positive women (59). In the same line with previous results from the Data 
collection on Adverse events of anti- HIV Drugs (D:A:D) study (60), the incidence rates for 
HTN increased with age in HIV- women and in HIV+ women on HAART. This can be 
supported as well by the Seventh report of the Joint National Committee on prevention, 
detection, evaluation, and treatment of high blood pressure results that showed that 
individuals who are normotensive at an older age have a lifetime high risk (90%) for 
developing HTN.   
The higher incidence of HTN in the HIV– participants might be explained partly by the older 
age of HIV- women. Another possible explanation could be the fact that HIV+ participants 
had much more counselling sessions and follow-up visits for the CD4 and viral load check-
ups, that could have raised their awareness on riskier behaviour related to HTN development 
and that might have rendered them much cautious about safer healthy measures like regular 
check-up, alcohol and smoking secession, and eating healthy foods, and early detection and 
treatment of pre-HTN cases.  
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Higher IRs of HTN were observed among overweight and obese HIV negative and HIV 
positive patients on HAART. There was no significant difference in the prevalence of obesity 
and mean BMI between HIV-positive HAART-naïve and HIV-positive on HAART 
participants. HTN is developed as a result of high blood pressure and it is strongly correlated 
with body mass index; overweight and obesity are determined from BMI and obesity was 
noted to be on its own a single best predictor of HTN incidence.  
A Ugandan population based survey on burden of HTN in a cohort established initially for 
HIV care showed similar findings, age and BMI were factors associated with high prevalence 
of HTN (61). Similarly, a South African study on HTN and obesity in adults living in a high 
HIV prevalence rural area found that both hypertension and obesity were significantly 
associated with age, female sex, HIV and being on HAART (62).   
The relationship between HTN and obesity has been described as multifaceted. Obesity was 
noted to be a single best predictor of HTN incidence and was regarded as a major controllable 
contributor to HTN (63). Overweight and obesity is conveniently determined from BMI.  
Dramatic advances in understanding the mechanisms of obesity – related HTN have been 
accomplished recently. Obesity was shown to be associated with several central and 
peripheral abnormalities that can explain the development or maintenance of high arterial BP.  
Clinical and animal studies have highlighted the key role of increased sympathetic activity in 
obesity-HTN. Several factors may account for the increase of sympathetic outflow associated 
with obesity such as the role of leptin, an adipocyte derived hormone that acts in the 
hypothalamus to regulate appetite and energy expenditure. In addition to its effect on 
sympathetic nervous system to the kidney, leptin may act directly on the kidney to increase 
oxidative stress, as evidenced by increased plasma concentration and urinary excretion of 
isoprostanes, increased level of lipid peroxidation products in renal homogenates, and 
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reduced renal aconitase activity (64). Long-term sympatho- activation could raise arterial 
pressure by causing peripheral vasoconstriction and by increasing renal tubular sodium 
reabsorption (65).   
Renal function abnormalities could be explained by several alterations in renal structure and 
function associated with obesity by the activation of the sympathetic nervous system and the 
Renin Angiotensin System (RAS) as well as increases in plasma aldosterone levels that can 
cause abnormal sodium retention and increase arterial pressure. Compression of the kidney 
by the surrounding fat and the renal structural changes associated with obesity may also play 
a role in the renal damage associated with obesity.  
Reduced activity of arachidonic acid pathways in renal tubular sites could be another 
potential explanation. Given the importance of arachidonic acid metabolic in inhibition of ion 
transport along the nephron, the down regulation of arachidonic acid pathways in obesity may 
be involved in the increased sodium reabsorption thereby promoting blood pressure elevation 
(66).  
The activation of the Renin- Angiotensin System (RAS) in obesity on its own plays a role in 
explaining obesity development. Adipose angiotensinogen is involved in adipose tissue 
growth and blood pressure regulation. It was demonstrated that adipocyte derived angiotensin 
can act locally to affect adipocytes growth and differentiation and/or may be released in the 
bloodstream and the high circulating levels of angiotensinogen associated partly to increase 
fat mass (67). 
The involvement of aldosterone in obesity associated HTN is another contributing factor in 
this process. It was established by blockade of mineralocorticoid receptors with the specific 
antagonist eplerenone located in different tissues, including the kidney, vasculature and brain, 
which inhibit the development of high BP without affecting the weight gain thus raising BP.  
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Damage to the endothelium is another important risk factor for CVDs as it leads to structural 
changes, such as thickening of the intima and media of the vessel wall. A number of 
mechanisms linking obesity with endothelial dysfunction are not yet fully clarified, several 
factors may contribute to this abnormality such as increased vascular production of 
endothelin-1 in hypertensive patients with increased body mass has been suggested as a 
potential mechanism for endothelial dysfunction (68).   
4.4. RISK FACTORS OF BP CHANGES IN THE COHORT 
Findings from this study indicate that at the baseline visit, HIV negative participants were 
older than their HIV positive counterparts, which may explain in part the observed 
statistically significant differences between HIV negative and HIV positive participants in 
terms of mean SBP and DBP measurements. These results are consistent with findings from 
the Framingham Heart study that documented increasing age as a long term risk factor for 
CVD (69). 
Our findings suggest that depression decreased the risk for HTN among HIV negative 
women. Similar findings were found in a Norwegian prospective study that looked at 
repeated assessment of depression levels. The authors found that symptoms of anxiety and 
depression were associated with a decrease in DBP, with an even stronger decrease in 
individuals with a high symptom level (70). Another study by Licht et al (71) that assessed 
whether depression was associated with decreased BP and the role of antidepressant use on 
the development of HTN showed that depressive disorders were associated with lower BP 
and less HTN. Unfortunately this study did not look at the association between the use of 
certain antidepressants and their effect on both high diastolic and systolic blood pressures and 
hypertension development. More possible explanations being, one a higher occurrence of 
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hypotensive episodes in individuals with depression and second, that depression alters the 
cicardian BP profile (72).  
Monthly income and being employed were found to be significant predictors of HTN among 
HIV positive women specifically among HAART naïve patients. These findings may be 
regarded as proxy measures of socio-economic status, which is believed to play an important 
role in all aspects of life. The findings are in line with a study done on association between 
wages and the development of HTN which showed strong association between wages and 
HTN among women aged 25- 44 year (73). The literature has been inconsistent about this 
association. In 1940 and 1960s studies in the US and UK found that high social economic 
status groups were at greater risk (74). 
This study found HDL levels to be associated with raised systolic blood pressure in HIV 
infected participants HAART naïve. In a study that looked at patterns of lipoprotein in the 
same cohort (57) found higher HDL levels to be associated with  increased alcohol use but in 
general HDL levels in this group were low. This finding may also be explained by the small 
sample size of the group and the changes associated with HIV infection such as chronic 
inflammation, hypercoagulability and platelet activation that contribute to endothelial 
dysfunction and later lead to CVD via different pathophysiological pathways (75).   
4. 5. STRENGTHS OF THE STUDY 
A few studies have determined the prevalence of HTN in the Rwandan population before;  
this is the first study to determine the incidence of HTN. The major strengths of this study lie 
in its prospective study design, three different comparison groups, and a substantial number 
of available BP measurements.  
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4.6. LIMITATIONS OF THE STUDY 
One of the limitations of this study was that it did not measure HAART use and duration on 
HAART and some of the well-known risk factors like smoking, alcohol consumption, 
physical exercise and salt intake. As the study was a secondary data analysis, there were 
missing data and unbalanced observations of the variables related to the research question 
being answered here, which made the statistical analysis difficult. The study included a 
cohort of women recruited from a women’s association in a Rwandan urban setting, and may 
not be representative for all Rwandan women and its results may only apply to women. This 









CONCLUSION AND RECOMMENDATIONS 
5.1. CONCLUSION 
Incidence rates of HTN were higher in HIV- compared with HIV positive counterparts. The 
findings also show that socio-economic factors such as income and employment status and 
lifestyle factors, for instance BMI and depression, were also associated with blood pressure 
changes. Given the worldwide medical, public health importance, and the low public 
awareness of risks and treatment of HTN in SSA (76, 77), a call for lifestyle changes through 
education of the population is key along with proper interventions both curative and 
preventive are needed. 
5.2. RECOMMENDATIONS 
A general comprehensive risk factor assessment for major chronic diseases of importance 
(hypertension, diabetes and non AIDS cancers) is needed while providing care to the 
Rwandan people. To help prevent complications of hypertensive disease, health care 
providers should educate the Rwandan population about potential risks of HTN among HIV 
negative and HIV positive patients (78) . 
Additional considerations should be given to potential drug interactions between 
antihypertensive agents and HAART to inform clinician selection of these therapies.  
 This study did not look at some of the risk factors for HTN such as alcohol consumption, 
smoking, and the role of regular physical activity and salt intake. (79). Hence, future studies 
including them are advised. 
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This study did not look at the relationship between specific antiretroviral therapy regimens 
and the development of HTN. A study with a larger sample size looking at this association is 
highly recommended. A similar study in male participants is also recommended as disparities 
between the two sexes are known. 
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GENERALIZED ESTIMATING EQUATION (GEE) METHOD REVIEW 
1. GENERALIZED ESTIMATION EQUATIONS MODELS 
GEE were introduced by Liang and Zeger (1986) (80) as a means of analysing longitudinal 
data. GEE are extensions of generalized linear regression models (GLM) that (81) account for 
repeated or dependent observations and allow specifying the working correlation structure. 
The estimation and inference procedures for GLM models are, in principle, analogous to 
those for GEE models (82). GEE are used to characterise the marginal expectation of a set of 
outcomes as a function of a set of study variables. The marginal mean model can be written 
as follows:  
 ijijijYg  ])|[(  
where 
ij is a p times 1 vector of explanatory variables (covariates) for the ith subject at the 
jth outcome,  consists of the p regression parameters of interest, ijY denotes thejth outcome 
(for j = 1,, J) for the ith subject (for i  = 1,,N) , and )(g  is a monotone, differentiable 
function called the link function.  
Common choices for the link function are aag )(  for continuous data (identity link), 
)log()( aag  for count data (log link), or )1/log()( aaag  for binary data (logit link). 
Other link functions exist (81). 
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In addition to the marginal mean model, the covariance structure of the correlated 
observations needs to be modelled on a given subject. Assuming no missing data, the J x J 
covariance matrix of Yi = (Yi1, Yi2,, YJ) is modelled as:   
2/12/1 )( iii RV    
where  is a GLM dispersion parameter, A is a diagonal matrix of variance functions, and 
)(R  is the working correlation matrix of i . 
When fitting the model in GEE, the model for the mean and for the variance and the fact that 
data are missing completely at random are considered.     
In GEE, model parameters and covariance structures are estimated as follows:  
Quasi- likelihood estimation, where only the mean and variance are specified, rather than a 
full probability model of its distribution. The Quasi likelihood approach is generalized to 
allow a choice of structures for the correlation of outcomes within clusters; these are working 
correlation structures.  
Robust standard errors are used to take account of the clustering, and the fact that the 
parameter estimates are not based on a full probability model. For normally distributed 
outcomes, parameter estimates from GEE are identical to those from the standard random-
effects models. GEE adjust for both standard errors and parameter estimates to allow for 
clustering (83).  
2. SPECIFICATION OF WORKING CORRELATION MATRIX 
Because the repeated observations within one subject are not independent of each other, a 
correlation must be made for these within-subject observations. GEE takes into account the 
dependency of observations by specifying a priori a working correlation structure.  There are 
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a variety of common structures (independent, exchangeable, autoregressive, stationary or m-
dependent and fixed) (81, 84) that may be appropriate. In general, if the number of 
observations per cluster is small in a balanced and complete design, an unstructured matrix is 
recommended (81). For datasets with mistimed measurements, a model where M-dependent 
or autoregressive correlation is a function of the time between observations may be 
reasonable (81). For datasets with clustered observations, where there is no logical ordering 
for observations within a cluster, an exchangeable structure may be most appropriate (81).  
1. Independent: with this structure the correlations between subsequent measurements 
are assumed to be zero therefore, the within- individual correlation matrix of the form:  
Estimated within individuals’ correlation matrix R: 
       c1             c2          c3          c4           c5           c6 
r1    1  0 0 0       0          0 
r2   0                1 0      0       0          0  
r3   0                0           1       0       0          0  
r4   0                0           0              1  0          0  
r5   0                0           0        0 1          0 
r6   0             0  0      0 0   1 
2. Autoregressive (1): the correlations one measurement apart are assumed to be ρ, two 
times measurement apart are assumed to be ρ2, correlations at time t are assumed to be 
ρ t. The term ρ is the intra-class correlation coefficient (ICC) and it is defined as the 
ratio of the between cluster variance to the total variance, which is the between and 
within cluster variances. Therefore, the within – individual correlation matrix R is of 
the form: 
  Estimated within individuals’ correlation matrix R: 
        c1           c2          c3             c4             c5           c6 
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r1          1       ρ1             ρ2             ρ3             ρ4             ρ5 
r2          ρ1           1        ρ1             ρ2             ρ3             ρ4 
r3          ρ2           ρ1            1        ρ1              ρ2             ρ3 
r4         ρ3            ρ2            ρ1                  1              ρ1             ρ2  
r5         ρ4            ρ3           ρ2             ρ1                   1               ρ1 
r6         ρ5           ρ4             ρ3            ρ2             ρ1             1 
 
3. Exchangeable (or compound symmetry): in this structure the correlations between 
subsequent measurements are assumed to be the same.    
Estimated within-individuals correlation matrix R: 
        c1           c2          c3           c4           c5           c6 
r1     1  ρ             ρρρρ 
r2     ρ            1 ρ             ρρρ 
r3     ρ            ρ            1 ρ             ρρ 
r4     ρ            ρρ             1             ρ              ρ 
r5     ρ            ρρρ            1              ρ  
r6    ρ            ρρρρ              1 
 
4. Unstructured: with this structure, all correlations are assumed to be different. 
 Estimated within-individuals correlation matrix R: 
        c1           c2          c3             c4            c5             c6 
r1     1   ρ1            ρ2             ρ3             ρ4             ρ5 
r2     ρ1            1   ρ6              ρ7             ρ8             ρ9 
r3     ρ2            ρ6            1     ρ10           ρ11            ρ12 
r4     ρ3            ρ7           ρ10             1             ρ13            ρ14 
r5     ρ4            ρ8           ρ11              ρ13            1            ρ15 
r6    ρ5            ρ9            ρ12              ρ14           ρ15           1 
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5. Stationary or m-dependent structure: assumes that the correlations t measurements 
apart are equal, the correlations t+1 measurements apart are assumed to be equal, and 
so on for t=1 to t=m. Correlations more than m measurements apart are assumed to be 
0.  
Estimated within-individuals correlation matrix R: 
         c1             c2         c3           c4           c5           c6 
r1     1   ρ1 ρ2 0             0             0 
r2    ρ1             1 ρ1 ρ2 0             0 
r3     ρ2           ρ1             1            ρ1 ρ2 0              
r4    0             ρ2             ρ1           1  ρ1 ρ2 
r5    0             0               ρ2          ρ1            1        ρ1 
r6    0  0   0            ρ2           ρ1           1 
GEE analysis presents a pooled analysis of longitudinal and cross-sectional relationships; in 
other words, it combines a within-individuals relation with a between-individuals 
relationship, resulting in one single regression coefficient. 
GEE models were used in this study due to analysing correlated longitudinal data as the 
interest was on the population averaged mean responses. The unstructured correlation was 
used due to missing values in some variables in the dataset. The exchangeable and 
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